Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn’s Disease

Abstract

We found that study participants with Crohn's disease who received mongersen had significantly higher rates of remission and clinical response than those who received placebo. (Funded by Giuliani; EudraCT number, 2011-002640-27.).